Tethis S.p.A.'s application note claims its SmartBioSurface slides hold immune cells from blood (peripheral blood mononuclear cells, or PBMCs) in place through ten rounds of a staining and erasing workflow that maps dozens of markers on one slide — but the spatial biology…
Spatial biology, a fast-growing field that maps dozens of molecular markers onto intact tissue, runs on a workflow that was designed for cells that stay put. The standard tool, a charged glass slide, is well matched to the tissue sections the field was built on. It is poorly matched to the cells that float in blood: peripheral blood mononuclear cells (PBMCs), which carry the immune system's day-to-day signal, and the rarer circulating tumor cells (CTCs) that oncologists want to track as they spread. Those cells do not stick. They round up, lift off, or get stripped away by the repeated cycles of staining, imaging, and signal erasure that a high-plex spatial panel requires, and the data goes with them.
A vendor application note released today by the Italian sample-prep company Tethis S.p.A. claims a concrete fix for that adhesion gap. The company's SmartBioSurface slides use a nanostructured coating designed to anchor suspension-derived cells through multi-round multiplex immunofluorescence, an imaging method that lets a single slide be stained, photographed, and then chemically erased and re-stained many times to build up a high-plex picture. Tethis's press release distributed via PRNewswire positions the slides as a drop-in substrate for an unnamed leading spatial-imaging platform.
The numbers in the application note are specific and, for now, vendor-supplied. Tethis reports more than twice the initial PBMC attachment versus standard charged glass controls, roughly 0.14% cell loss per imaging cycle, and approximately 98.5% retention after ten cycles. The company also says the slides hold up after two weeks at 4 °C post-fixation, and that a 15-plex immune panel produced signal-to-noise ratios (SNR) above the defined threshold for every marker measured. None of those figures is independently corroborated in the release, and the protocol, the comparator glass-slide identity, and the imaging-cycle definitions live in the application note PDF itself.
The underlying problem is real and widely recognized in the field. Multi-cycle, high-plex imaging of suspension-derived cells is a known bottleneck for integrating blood-based and tissue spatial data, and any working sample-prep solution is an enabling result for translational research. A substrate that holds a PBMC, or a CTC, through ten rounds of staining and stripping would open up immune-monitoring and liquid-biopsy workflows that today have to be run separately from tissue spatial work. The only public data on whether SmartBioSurface actually delivers that is from Tethis's own study, on cells the company prepared, on a platform the company declines to name.
The open questions for a reader weighing this are concrete. Which instrument is the substrate being benchmarked against, and on whose workflow? Has a core facility, a translational immunology lab, or a spatial-omics principal investigator run a head-to-head comparison against the glass slides they currently use? And does the retention hold up on rarer, more fragile targets than cryopreserved PBMCs, which were the test case in the application note? Until at least one of those questions gets an answer from a source other than the vendor, the read of today's announcement is that a known workflow gap now has a named, vendor-tested substrate aimed at it, with the integration story and the independent benchmark still to come.